PTC Therapeutics Grants Stock Options and RSUs to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy PTCT?
Source: PRnewswire
- Stock Option Grant: On December 16, 2025, PTC Therapeutics approved the grant of 3,825 stock options and 4,385 restricted stock units to five new employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Structure: All stock options have an exercise price of $75.42 per share, aligning with Nasdaq's inducement grant exception, reflecting the company's commitment to incentivizing new hires.
- Long-term Vesting: The stock options vest over four years, with 25% vesting in the first year and 6.25% every three months thereafter, ensuring continued employee contribution during their tenure.
- Strategic Talent Acquisition: This grant of stock options and RSUs not only enhances the company's ability to attract and retain key talent but also supports its innovative development in the rare disease sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTCT
Wall Street analysts forecast PTCT stock price to rise
14 Analyst Rating
8 Buy
5 Hold
1 Sell
Moderate Buy
Current: 70.700
Low
54.00
Averages
78.18
High
118.00
Current: 70.700
Low
54.00
Averages
78.18
High
118.00
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PTC Therapeutics Withdraws New Drug Application for Translarna
- Withdrawal of NDA: PTC Therapeutics has withdrawn its New Drug Application for Translarna (ataluren) after receiving FDA feedback indicating that the submitted data was unlikely to meet effectiveness standards, marking a significant setback after over two decades of development for this Duchenne muscular dystrophy (DMD) therapy.
- Poor Market Performance: PTC's stock closed 5.16% lower on Thursday, currently trading 10.0% below its 20-day simple moving average, indicating a bearish short-term trend, and significantly underperforming compared to the flat performance of the healthcare sector.
- Future Earnings Outlook: PTC is set to report earnings on February 19, 2026, with an estimated loss of 34 cents per share and revenue forecasted at $290.76 million, up from $213.17 million year-over-year, suggesting potential growth opportunities despite current challenges.
- Analyst Rating Changes: While PTC's stock carries a
See More
PTC Therapeutics Withdraws NDA Resubmission for Translarna
- Application Withdrawal: PTC Therapeutics announced the withdrawal of its NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy, resulting in a ~5% drop in after-hours trading.
- FDA Feedback Impact: The decision was based on feedback from the US FDA regarding the application review, with CEO Matthew Klein stating that the data included is “unlikely to meet the Agency's threshold of substantial evidence of effectiveness.”
- European Market Status: Despite the withdrawal in the US, Translarna is approved in the European Union, highlighting regulatory differences across markets for the same drug.
- Future Revenue Outlook: PTC Therapeutics projects FY26 product revenue between $700 million and $800 million, indicating a positive outlook for the company despite the challenges posed by the FDA.
See More
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
- FDA Feedback Impact: PTC Therapeutics announced the withdrawal of its NDA for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy due to FDA feedback indicating that the submitted data is unlikely to meet effectiveness standards, resulting in the company being unable to secure approval after two decades of effort, which negatively impacts its market outlook.
- Drug Background: Translarna is a protein restoration therapy aimed at genetic disorders caused by nonsense mutations, primarily affecting patients with Duchenne muscular dystrophy who face severe health risks due to the lack of functional dystrophin protein, and the withdrawal of the application will limit treatment options for these patients.
- Market Impact: This withdrawal may diminish PTC's competitiveness in the biopharmaceutical market, particularly in the rare disease treatment sector, potentially affecting investor confidence and exerting downward pressure on the company's stock price.
- Future Outlook: Despite the withdrawal, PTC remains committed to developing innovative therapies for rare diseases and may reassess its R&D strategy in response to FDA feedback to seek approval for alternative treatment options.
See More
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
- FDA Feedback Impact: PTC Therapeutics announced the withdrawal of its NDA for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy due to FDA feedback indicating that the submitted data is unlikely to meet the effectiveness threshold, resulting in a significant setback for the company in drug development.
- Challenging R&D Journey: After over 20 years of effort to develop a safe and effective treatment, the FDA's rejection poses major challenges for PTC in meeting patient needs, impacting market confidence and future investments.
- Overview of Duchenne Muscular Dystrophy: This disease primarily affects males, leading to progressive muscle weakness and premature death in the mid-20s due to heart and respiratory failure; PTC's Translarna aimed to restore functional protein but failed to gain FDA approval, limiting its market potential.
- Strategic Company Reevaluation: PTC must reassess its product pipeline and market strategy in response to the FDA's negative feedback to ensure it can meet unmet medical needs and optimize its commercial value in the future.
See More
Rare Disease Biotechs Show Strong 2025 Performance with Cashflow and R&D Expansion
- Performance Breakthrough: Alnylam Pharmaceuticals achieved nearly $3 billion in sales in 2025 and projects sales of up to $5.3 billion in 2026, demonstrating strong growth potential in the rare disease sector.
- R&D Progress: Ultragenyx anticipates two gene therapy approvals in 2026 despite facing clinical trial setbacks in 2025, indicating ongoing investment and risk management in its development pipeline.
- Regulatory Support: The FDA's recent implementation of the Rare Disease Evidence Principles framework allows for therapy approvals based on single-arm studies, showcasing support for rare disease developers and potentially accelerating new therapies to market.
- Financial Outlook: PTC closed 2025 with $1.94 billion in cash reserves and plans to continue the global launch of its flagship product Sephience in 2026, aiming for break-even cash flow, reflecting robust development in the market.
See More
PTC Therapeutics Launches Sephience™ with Q4 Revenue of $92.5M
- Strong Revenue Performance: PTC Therapeutics reported global revenue of $92.5 million in Q4 2025, indicating robust market acceptance and demand for Sephience™, which is expected to drive future growth for the company.
- Exceeding Revenue Guidance: The total product and royalty revenue for 2025 is approximately $823 million, surpassing company expectations and reflecting the success and market potential of its product line, thereby enhancing investor confidence.
- 2026 Growth Outlook: PTC anticipates product revenue for 2026 to range between $700 million and $800 million, representing a year-over-year growth of 19% to 36%, indicating a positive outlook for new product launches and market expansion.
- Strong Cash Position: As of December 31, 2025, PTC holds approximately $1.94 billion in cash reserves, providing ample funding for future R&D and marketing efforts, supporting its goal of achieving cash flow breakeven.
See More
PTC Therapeutics Withdraws New Drug Application for Translarna
- Withdrawal of NDA: PTC Therapeutics has withdrawn its New Drug Application for Translarna (ataluren) after receiving FDA feedback indicating that the submitted data was unlikely to meet effectiveness standards, marking a significant setback after over two decades of development for this Duchenne muscular dystrophy (DMD) therapy.
- Poor Market Performance: PTC's stock closed 5.16% lower on Thursday, currently trading 10.0% below its 20-day simple moving average, indicating a bearish short-term trend, and significantly underperforming compared to the flat performance of the healthcare sector.
- Future Earnings Outlook: PTC is set to report earnings on February 19, 2026, with an estimated loss of 34 cents per share and revenue forecasted at $290.76 million, up from $213.17 million year-over-year, suggesting potential growth opportunities despite current challenges.
- Analyst Rating Changes: While PTC's stock carries a
See More
PTC Therapeutics Withdraws NDA Resubmission for Translarna
- Application Withdrawal: PTC Therapeutics announced the withdrawal of its NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy, resulting in a ~5% drop in after-hours trading.
- FDA Feedback Impact: The decision was based on feedback from the US FDA regarding the application review, with CEO Matthew Klein stating that the data included is “unlikely to meet the Agency's threshold of substantial evidence of effectiveness.”
- European Market Status: Despite the withdrawal in the US, Translarna is approved in the European Union, highlighting regulatory differences across markets for the same drug.
- Future Revenue Outlook: PTC Therapeutics projects FY26 product revenue between $700 million and $800 million, indicating a positive outlook for the company despite the challenges posed by the FDA.
See More
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
- FDA Feedback Impact: PTC Therapeutics announced the withdrawal of its NDA for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy due to FDA feedback indicating that the submitted data is unlikely to meet effectiveness standards, resulting in the company being unable to secure approval after two decades of effort, which negatively impacts its market outlook.
- Drug Background: Translarna is a protein restoration therapy aimed at genetic disorders caused by nonsense mutations, primarily affecting patients with Duchenne muscular dystrophy who face severe health risks due to the lack of functional dystrophin protein, and the withdrawal of the application will limit treatment options for these patients.
- Market Impact: This withdrawal may diminish PTC's competitiveness in the biopharmaceutical market, particularly in the rare disease treatment sector, potentially affecting investor confidence and exerting downward pressure on the company's stock price.
- Future Outlook: Despite the withdrawal, PTC remains committed to developing innovative therapies for rare diseases and may reassess its R&D strategy in response to FDA feedback to seek approval for alternative treatment options.
See More
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
- FDA Feedback Impact: PTC Therapeutics announced the withdrawal of its NDA for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy due to FDA feedback indicating that the submitted data is unlikely to meet the effectiveness threshold, resulting in a significant setback for the company in drug development.
- Challenging R&D Journey: After over 20 years of effort to develop a safe and effective treatment, the FDA's rejection poses major challenges for PTC in meeting patient needs, impacting market confidence and future investments.
- Overview of Duchenne Muscular Dystrophy: This disease primarily affects males, leading to progressive muscle weakness and premature death in the mid-20s due to heart and respiratory failure; PTC's Translarna aimed to restore functional protein but failed to gain FDA approval, limiting its market potential.
- Strategic Company Reevaluation: PTC must reassess its product pipeline and market strategy in response to the FDA's negative feedback to ensure it can meet unmet medical needs and optimize its commercial value in the future.
See More
Rare Disease Biotechs Show Strong 2025 Performance with Cashflow and R&D Expansion
- Performance Breakthrough: Alnylam Pharmaceuticals achieved nearly $3 billion in sales in 2025 and projects sales of up to $5.3 billion in 2026, demonstrating strong growth potential in the rare disease sector.
- R&D Progress: Ultragenyx anticipates two gene therapy approvals in 2026 despite facing clinical trial setbacks in 2025, indicating ongoing investment and risk management in its development pipeline.
- Regulatory Support: The FDA's recent implementation of the Rare Disease Evidence Principles framework allows for therapy approvals based on single-arm studies, showcasing support for rare disease developers and potentially accelerating new therapies to market.
- Financial Outlook: PTC closed 2025 with $1.94 billion in cash reserves and plans to continue the global launch of its flagship product Sephience in 2026, aiming for break-even cash flow, reflecting robust development in the market.
See More
PTC Therapeutics Launches Sephience™ with Q4 Revenue of $92.5M
- Strong Revenue Performance: PTC Therapeutics reported global revenue of $92.5 million in Q4 2025, indicating robust market acceptance and demand for Sephience™, which is expected to drive future growth for the company.
- Exceeding Revenue Guidance: The total product and royalty revenue for 2025 is approximately $823 million, surpassing company expectations and reflecting the success and market potential of its product line, thereby enhancing investor confidence.
- 2026 Growth Outlook: PTC anticipates product revenue for 2026 to range between $700 million and $800 million, representing a year-over-year growth of 19% to 36%, indicating a positive outlook for new product launches and market expansion.
- Strong Cash Position: As of December 31, 2025, PTC holds approximately $1.94 billion in cash reserves, providing ample funding for future R&D and marketing efforts, supporting its goal of achieving cash flow breakeven.
See More
